Pre-conception + prenatal carrier screening
Carrier screening for family planning.
Let knowledge be your guide. Identify genetic conditions before or during a pregnancy to help predict the chances of having a child with a genetic disorder.
Knowledge is the key to planning. Sequenom Laboratories’ carrier screening tests are designed to detect mutations associated with a broad array of clinically relevant genetic conditions before or during a pregnancy to help predict a family’s chances of having a child with a genetic disorder.
Noninvasive prenatal testing
Gain insight as early as nine weeks with the ease of a blood draw.
To fit the specific needs of each patient, Sequenom Laboratories offers an expansive selection of highly accurate noninvasive prenatal testing (NIPT) options for the detection of chromosomal abnormalities.
Sequenom Laboratories offers a simple blood test that can reveal mother-baby RHD incompatibility which, without treatment, can lead to RHD disease with serious and even fatal outcomes.
Prenatal diagnostic testing
Sequenom Laboratories is here for you throughout your genetic information-gathering journey.
Based on each patient’s personal characteristics and knowledge gained from prenatal ultrasound or NIPT screening, further insight may be needed to chart an informed course for mother and baby. Our full line of invasive laboratory-developed tests provides a fast and accurate prenatal diagnosis.
Pioneering purposeful innovation
As the pioneer of the noninvasive prenatal testing (NIPT) industry, Sequenom Laboratories was the first to offer a safe, reliable noninvasive prenatal testing method. We have been the market leader in this space ever since delivering a constant stream of purposeful innovation.
Major milestones in reproductive health
Launch of the HerediT® Cystic Fibrosis Carrier Screening laboratory-developed test, which offered superior detection rates and broader ethnic coverage when compared to the standard ACMG 23 recommended mutations panel.
The SensiGene® Fetal RHD Genotyping laboratory-developed test became the world’s first NIPT to detect circulating cell-free fetal DNA from maternal blood.
We announced the first NIPT for fetal chromosome 21 aneuploidy or trisomy 21 (Down syndrome) in the MaterniT® 21 laboratory-developed test.
The MaterniT® 21 PLUS laboratory-developed test added trisomy 18, trisomy 13, and fetal sex to the original analysis and also validated the test for use with multiple gestations.
MaterniT® 21 PLUS is enhanced with testing for sex chromosomes aneuploidies, several microdeletions, and trisomies 22 and 16.
Still more additions to the MaterniT® 21 PLUS test allowed for the detection of additional microdeletions.
We launched the MaterniT® GENOME laboratory-developed test, the first genome-wide NIPT.